For the Inventor, By the Inventor

Enter assignee name

Cambridge, MA, United States of America

Vertex Pharmaceuticals, Inc.

USPTO Granted Patents = 1,152

CIPO Patents = 46

EPO Patents = 308

Trademarks = 47

Forward Citations = 25,944

Loading Chart...

Loading Chart...

945 inventors (with patents filed for the assignee):

Jean-Damien Charrier (139 out of 140 patents)

Mark Thomas Miller (105 out of 111 patents)

Jinglan Zhou (101 out of 104 patents)

4. Sara Sabina Hadida Ruah (99 out of 99 patents)

5. Ronald Marcellus Knegtel (99 out of 100 patents)

6. Andreas Peter Termin (86 out of 98 patents)

7. David J Lauffer (82 out of 89 patents)

8. Guy W Bemis (82 out of 83 patents)

9. Jason McCartney (74 out of 74 patents)

10. Brian Richard Bear (73 out of 75 patents)

11. Peter D J Grootenhuis (69 out of 70 patents)

12. Steven John Durrant (69 out of 70 patents)

13. Albert Charles Pierce (66 out of 66 patents)

14. Paul S Charifson (63 out of 65 patents)

15. Pan Li (58 out of 58 patents)

Core Competencies:

Cystic Fibrosis

Sodium Channel Modulators

Pancreatic Endocrine Cells

Genome Editing

APOL1 Inhibitors

Pharmaceutical Compositions

Stem Cell Differentiation

Hemoglobinopathies

DNA-PK Inhibitors

Therapeutic Delivery Devices

Alpha-1 Antitrypsin Modulators

Indole Derivatives

1,152 patents: Sort by Forward Citations

1. 12508231 - Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (2025-12-30),

2. 12503439 - Heteroaryl compounds for the treatment of pain (2025-12-23),

3. 12502376 - Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD) (2025-12-23),

4. 12458635 - Pharmaceutical composition and administrations thereof (2025-11-04),

5. 12442020 - Materials and methods for treatment of pain related disorders (2025-10-14),

6. 12441703 - Carboxamides as modulators of sodium channels (2025-10-14),

7. 12440481 - Esters and carbamates as modulators of sodium channels (2025-10-14),

8. 12421251 - Cystic fibrosis transmembrane conductance regulator modulating agents (2025-09-23),

9. 12421249 - Inhibitors of APOL1 and methods of using same (2025-09-23),

10. 12415798 - Processes for making modulators of cystic fibrosis transmembrane conductance regulator (2025-09-16),

11. 12385013 - Differentiation of pancreatic endocrine cells (2025-08-12),

12. 12384790 - Pteridinone compounds and uses thereof (2025-08-12),

13. 12384762 - Modulator of the Cystic Fibrosis Transmembrane Conductance Regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator (2025-08-12),

14. 12377252 - Implantation devices, system, and methods (2025-08-05),

15. 12371665 - Differentiation of pancreatic endocrine cells (2025-07-29),

Vertex Pharmaceuticals is a global biotechnology company that aims to discover, develop, and commercialize innovative medicines for serious diseases. With a focus on cystic fibrosis and other severe pulmonary diseases, Vertex is committed to transforming patients' lives with groundbreaking therapies. Through cutting-edge scientific research and collaborations, Vertex strives to provide hope and improved treatment options to those in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

1,152 Patents

#4 in Cambridge, MA

#24 in Massachusetts

#435 in US

#868 in the World

Cambridge, MA, United States of America

Vertex Pharmaceuticals, Inc.

Forward Citations = 25,944

945 inventors:

Jean-Damien Charrier (139 out of 140 patents)

Mark Thomas Miller (105 out of 111 patents)

Jinglan Zhou (101 out of 104 patents)

4. Sara Sabina Hadida Ruah (99 out of 99 patents)

5. Ronald Marcellus Knegtel (99 out of 100 patents)

Please report any incorrect information to support@idiyas.com

Loading…